NYSE - Nasdaq Real Time Price USD

Artivion, Inc. (AORT)

29.40

+0.78

+(2.74%)

As of 1:22:50 PM EDT. Market Open.

Returns On Capital At Artivion (NYSE:AORT) Have Stalled

What are the early trends we should look for to identify a stock that could multiply in value over the long term...

Simply Wall St. 2 days ago

AORT
+2.74%
Artivion Announces Agreements to Exchange $95 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it entered into separate, privately negotiated exchange agreements with certain holders of its 4.250% Convertible Senior Notes due 2025 (the "Existing Convertible Notes"). Under the exchange agreements, the company will, subject to customary closing conditions, repurchase approximately $95 million principal amount of Existing Convertible Notes in exchange for a number of sh

PR Newswire 12 days ago

AORT
+2.74%
Artivion Reports First Quarter 2025 Financial Results

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the first quarter ended March 31, 2025.

PR Newswire 21 days ago

AORT
+2.74%
Artivion Announces Presentation of New Clinical Data from NEXUS TRIOMPHE IDE Trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from Endospan's NEXUS TRIOMPHE trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting in Seattle, Washington. The data presented analyzed clinical outcomes across a 54-patient chronic aortic dissection statistical cohort at 30 days following treatment with NEXUS. Patients enrolled were at high risk for open surgic

PR Newswire 22 days ago

AORT
+2.74%
Artivion Announces Release Date and Teleconference Call Details for First Quarter 2025 Financial Results

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2025 financial results will be released on Monday, May 5, 2025, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question-and-answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of Artivion.

PR Newswire last month

AORT
+2.74%
Investors in Artivion (NYSE:AORT) have seen returns of 15% over the past year

It hasn't been the best quarter for Artivion, Inc. ( NYSE:AORT ) shareholders, since the share price has fallen 21% in...

Simply Wall St. last month

AORT
+2.74%
Do Options Traders Know Something About Artivion (AORT) Stock We Don't?

Investors need to pay close attention to Artivion (AORT) stock based on the movements in the options market lately.

Zacks 2 months ago

AORT
+2.74%
Artivion to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming Oppenheimer 35th Annual Healthcare MedTech & Services Conference. The Company's virtual fireside chat is scheduled to begin at 10:40 a.m. ET on March 18, 2025.

PR Newswire 2 months ago

AORT
+2.74%
Artivion Full Year 2024 Earnings: EPS Misses Expectations

Artivion ( NYSE:AORT ) Full Year 2024 Results Key Financial Results Revenue: US$388.5m (up 9.8% from FY 2023). Net...

Simply Wall St. 2 months ago

AORT
+2.74%
Down -18.58% in 4 Weeks, Here's Why Artivion (AORT) Looks Ripe for a Turnaround

Artivion (AORT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks 2 months ago

AORT
+2.74%
Earnings Miss: Artivion, Inc. Missed EPS And Analysts Are Revising Their Forecasts

It's been a mediocre week for Artivion, Inc. ( NYSE:AORT ) shareholders, with the stock dropping 13% to US$25.42 in the...

Simply Wall St. 2 months ago

AORT
+2.74%
Artivion price target lowered to $32 from $34 at Needham

Needham lowered the firm’s price target on Artivion (AORT) to $32 from $34 and keeps a Buy rating on the shares after its Q4 results. The company’s constant currency revenue growth slowed to 3.5% from 9.5% in Q3 as the previously disclosed cybersecurity issue disrupted sales while its gross margin was down 200 bps, the analyst tells investors in a research note. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-perfor

TipRanks 2 months ago

AORT
+2.74%
Artivion Reports Fourth Quarter and Full Year 2024 Financial Results

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the fourth quarter and year ended December 31, 2024.

PR Newswire 2 months ago

AORT
+2.74%
Should You Investigate Artivion, Inc. (NYSE:AORT) At US$28.26?

Artivion, Inc. ( NYSE:AORT ), might not be a large cap stock, but it received a lot of attention from a substantial...

Simply Wall St. 2 months ago

AORT
+2.74%
Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2024 Financial Results

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2024 financial results will be released on Monday, February 24, 2025 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of Artivion.

PR Newswire 3 months ago

AORT
+2.74%
Estimating The Fair Value Of Artivion, Inc. (NYSE:AORT)

Key Insights The projected fair value for Artivion is US$32.80 based on 2 Stage Free Cash Flow to Equity Artivion's...

Simply Wall St. 3 months ago

AORT
+2.74%
Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 61st Society of Thoracic Surgery Annual Meeting

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced data from the AMDS PERSEVERE clinical trial (the "IDE") was presented in a Late-Breaking Science presentation at the 61st Annual Meeting of the Society of Thoracic Surgeons in Los Angeles, California. The data presented analyzed clinical outcomes across the full 93 study participant IDE cohort at one year following AMDS implantation.

PR Newswire 3 months ago

AORT
+2.74%
3 US Stocks Estimated To Be Trading Below Their Intrinsic Value In January 2025

As the U.S. stock market navigates a mixed landscape marked by fluctuating tech stocks and rising bond yields, investors are keeping a close eye on economic indicators such as inflation data and interest rate decisions from the Federal Reserve. Amidst these uncertainties, identifying stocks that may be trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on mispriced assets in an evolving market environment.

Simply Wall St. 4 months ago

AORT
+2.74%

ENFN

PNTG
Artivion Granted FDA Humanitarian Device Exemption for the AMDS Hybrid Prosthesis

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted a Humanitarian Device Exemption (HDE) for use of the AMDS Hybrid Prosthesis ("AMDS") in acute DeBakey Type I dissections in the presence of malperfusion. The AMDS is the world's first aortic arch remodeling device for use in the treatment of acute DeBakey Type I aortic dissections.

PR Newswire 5 months ago

AORT
+2.74%
Returns On Capital Are Showing Encouraging Signs At Artivion (NYSE:AORT)

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Typically...

Simply Wall St. 5 months ago

AORT
+2.74%

Performance Overview

Return	AORT	S&P 500 (^GSPC)
YTD	+2.82%	+0.57%
1-Year	+23.61%	+11.50%
3-Year	+50.98%	+42.25%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Artivion, Inc. (AORT)

Returns On Capital At Artivion (NYSE:AORT) Have Stalled

Artivion Announces Agreements to Exchange $95 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock

Artivion Reports First Quarter 2025 Financial Results

Artivion Announces Presentation of New Clinical Data from NEXUS TRIOMPHE IDE Trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting

Artivion Announces Release Date and Teleconference Call Details for First Quarter 2025 Financial Results

Investors in Artivion (NYSE:AORT) have seen returns of 15% over the past year

Do Options Traders Know Something About Artivion (AORT) Stock We Don't?

Artivion to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

Artivion Full Year 2024 Earnings: EPS Misses Expectations

Down -18.58% in 4 Weeks, Here's Why Artivion (AORT) Looks Ripe for a Turnaround

Earnings Miss: Artivion, Inc. Missed EPS And Analysts Are Revising Their Forecasts

Artivion price target lowered to $32 from $34 at Needham

Artivion Reports Fourth Quarter and Full Year 2024 Financial Results

Should You Investigate Artivion, Inc. (NYSE:AORT) At US$28.26?

Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2024 Financial Results

Estimating The Fair Value Of Artivion, Inc. (NYSE:AORT)

Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 61st Society of Thoracic Surgery Annual Meeting

3 US Stocks Estimated To Be Trading Below Their Intrinsic Value In January 2025

Artivion Granted FDA Humanitarian Device Exemption for the AMDS Hybrid Prosthesis

Returns On Capital Are Showing Encouraging Signs At Artivion (NYSE:AORT)

Performance Overview